Everolimus But Not Mycophenolate Mofetil Therapy Is Associated With Soluble HLA-G Expression in Heart Transplant Patients

Journal of Heart and Lung Transplantation

Volumn 28, Issue 11, 2009, Pages 1193-1197

  Sheshgiri, Rohit ^a   Gustafsson, Finn ^b   Sheedy, Jill ^a   Rao, Vivek ^a   Ross, Heather J ^a   Delgado, Diego H ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; EVEROLIMUS; HLA G ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; AREA UNDER CURVE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MATERNAL-FETAL EXCHANGE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; PREGNANCY; PREGNANCY PROTEINS; SIROLIMUS;

EID: 70350046429     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.07.009     Document Type: Article

References (39)

1. Kovats S., Main E.K., Librach C., et al. A class I antigen, HLA-G, expressed in human trophoblasts. Science 248 (1990) 220-223
2. McMaster M.T., Librach C.L., Zhou Y., et al. Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J Immunol 154 (1995) 3771-3778
3. Ishitani A., and Geraghty D.E. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci USA 89 (1992) 3947-3951
4. Paul P., Cabestre F.A., Ibrahim E.C., et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol 61 (2000) 1138-1149
5. Le Gal F.A., Riteau B., Sedlik C., et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 11 (1999) 1351-1356
6. Bainbridge D., Ellis S.A., and Sargent I.L. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol 48 (2000) 17-26
7. Fournel S., Aguerre-Girr M., Huc X., et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 164 (2000) 6100-6104
8. Bahri R., Hirsch F., Josse A., et al. Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol 176 (2006) 1331-1339
9. Rouas-Freiss N., Marchal R.E., Kirszenbaum M., et al. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?. Proc Natl Acad Sci USA 94 (1997) 5249-5254
10. Rouas-Freiss N., Goncalves R.M., Menier C., et al. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 94 (1997) 11520-11525
11. Horuzsko A., Lenfant F., Munn D.H., et al. Maturation of antigen-presenting cells is compromised in HLA-G transgenic mice. Int Immunol 13 (2001) 385-394
12. Ristich V., Liang S., Zhang W., et al. Tolerization of dendritic cells by HLA-G. Eur J Immunol 35 (2005) 1133-1142
13. LeMaoult J., Krawice-Radanne I., Dausset J., et al. HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc Natl Acad Sci USA 101 (2004) 7064-7069
14. Le Rond S., Azema C., Krawice-Radanne I., et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells. J Immunol 176 (2006) 3266-3276
15. Rouas-Freiss N., Naji A., Durrbach A., et al. Tolerogenic functions of human leukocyte antigen G: from pregnancy to organ and cell transplantation. Transplantation 84 suppl (2007) S21-S25
16. Rouas-Freiss N., Moreau P., Menier C., et al. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol 17 (2007) 413-421
17. Carosella E.D., Moreau P., Aractingi S., et al. HLA-G: a shield against inflammatory aggression. Trends Immunol 22 (2001) 553-555
18. Lila N., Carpentier A., Amrein C., et al. Implication of HLA-G molecule in heart-graft acceptance. Lancet 355 (2000) 2138
19. Lila N., Amrein C., Guillemain R., et al. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 105 (2002) 1949-1954
20. Luque J., Torres M.I., Aumente M.D., et al. Soluble HLA-G in heart transplantation: their relationship to rejection episodes and immunosuppressive therapy. Hum Immunol 67 (2006) 257-263
21. Luque J., Torres M.I., Aumente M.D., et al. sHLA-G levels in the monitoring of immunosuppressive therapy and rejection following heart transplantation. Transplant Immunol 17 (2006) 70-73
22. Lila N., Amrein C., Guillemain R., et al. Soluble human leukocyte antigen-G: a new strategy for monitoring acute and chronic rejections after heart transplantation. J Heart Lung Transplant 26 (2007) 421-422
23. Sheshgiri R., Rouas-Freiss N., Rao V., et al. Myocardial HLA-G reliably indicates a low risk of acute cellular rejection in heart transplant recipients. J Heart Lung Transplant 27 (2008) 522-527
24. Creput C., Durrbach A., Menier C., et al. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol 39 (2003) 587-594
25. Creput C., Le Friec G., Bahri R., et al. Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver-kidney transplantation: possible implications for monitoring patients. Hum Immunol 64 (2003) 1033-1038
26. Basturk B., Karakayali F., Emiroglu R., et al. Human leukocyte antigen-G, a new parameter in the follow-up of liver transplantation. Transplant Proc 38 (2006) 571-574
27. Qiu J., Terasaki P.I., Miller J., et al. Soluble HLA-G expression and renal graft acceptance. Am J Transplant 6 (2006) 2152-2156
28. Crispim J.C., Duarte R.A., Soares C.P., et al. Human leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection. Transplant Immunol 18 (2008) 361-367
29. Hviid T.V., Hylenius S., Rorbye C., et al. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics 55 (2003) 63-79
30. Rebmann V., van der Ven K., Passler M., et al. Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens 57 (2001) 15-21
31. Yie S.M., Li L.H., Li G.M., et al. Progesterone enhances HLA-G gene expression in JEG-3 choriocarcinoma cells and human cytotrophoblasts in vitro. Hum Reprod 21 (2006) 46-51
32. Yang Y., Chu W., Geraghty D.E., et al. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma. J Immunol 156 (1996) 4224-4231
33. Lefebvre S., Moreau P., Guiard V., et al. Molecular mechanisms controlling constitutive and IFN-gamma-inducible HLA-G expression in various cell types. J Reprod Immunol 43 (1999) 213-224
34. Yang Y., Geraghty D.E., and Hunt J.S. Cytokine regulation of HLA-G expression in human trophoblast cell lines. J Reprod Immunol 29 (1995) 179-195
35. Moreau P., Adrian-Cabestre F., Menier C., et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 11 (1999) 803-811
36. Sheshgiri R., Rao V., Tumiati L.C., et al. Progesterone induces human leukocyte antigen-G expression in vascular endothelial and smooth muscle cells. Circulation 118 suppl (2008) S58-S64
37. Mouillot G., Marcou C., Zidi I., et al. Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol 68 (2007) 277-285
38. Rudstein-Svetlicky N., Loewenthal R., Horejsi V., et al. HLA-G levels in serum and plasma. Tissue Antigens 67 (2006) 111-116
39. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847-858